GAIN THERAPEUTICS, INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
GAIN THERAPEUTICS, INC (GANX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 798.50 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-11
- GAIN THERAPEUTICS, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares.
- GAIN THERAPEUTICS, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 798.50K shares.
- GAIN THERAPEUTICS, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-12-31 was -1.00 shares, a 100.04% decline year-over-year.
- GAIN THERAPEUTICS, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- GAIN THERAPEUTICS, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 1.20M shares, a 14.13% decline from fiscal 2024.
- GAIN THERAPEUTICS, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.40M shares, a 94.29% increase from fiscal 2023.
- GAIN THERAPEUTICS, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 721.85K shares, a 28.23% decline from fiscal 2022.
- GAIN THERAPEUTICS, INC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.01M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 798.50K shares 10-Q · filed 2026-08-11 | ||
| 2026-03-31 | 798.50K shares 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | 1.20M shares 10-K · filed 2026-03-26 | |||
| 2024-12-31 | 1.40M shares 10-K · filed 2025-03-27 | |||
| 2023-12-31 | -1.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -1.00 shares derived: sum of 2 quarters · filed 2024-03-26 | 163.00K shares derived: sum of 3 quarters · filed 2024-03-26 | 721.85K shares 10-K · filed 2024-03-26 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 163.00K shares derived: sum of 2 quarters · filed 2023-11-14 | 721.85K shares 10-Q · filed 2023-11-14 | 724.35K shares derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | 163.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 721.85K shares 10-Q · filed 2023-08-10 | 724.35K shares derived: sum of 3 quarters · filed 2023-08-10 | 1.43M shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 558.85K shares 10-Q · filed 2023-05-12 | 561.35K shares derived: sum of 2 quarters · filed 2023-05-12 | 1.27M shares derived: sum of 3 quarters · filed 2023-05-12 | |
| 2022-12-31 | 2.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | 709.00K shares derived: sum of 2 quarters · filed 2023-03-23 | 1.01M shares 10-K · filed 2023-03-23 | |
| 2022-09-30 | 706.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | 1.00M shares 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | 296.80K shares 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |